Cargando…
Switching on the green light for chimeric antigen receptor T‐cell therapy
Adoptive cellular therapy involving genetic modification of T cells with chimeric antigen receptor (CAR) transgene offers a promising strategy to broaden the efficacy of this approach for the effective treatment of cancer. Although remarkable antitumor responses have been observed following CAR T‐ce...
Autores principales: | Mardiana, Sherly, Lai, Junyun, House, Imran Geoffrey, Beavis, Paul Andrew, Darcy, Phillip Kevin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6500780/ https://www.ncbi.nlm.nih.gov/pubmed/31073403 http://dx.doi.org/10.1002/cti2.1046 |
Ejemplares similares
-
CAR T cells take centre stage
por: Beavis, Paul A, et al.
Publicado: (2019) -
Selecting costimulatory domains for chimeric antigen receptors: functional and clinical considerations
por: Weinkove, Robert, et al.
Publicado: (2019) -
Clinical chimeric antigen receptor‐T cell therapy: a new and promising treatment modality for glioblastoma
por: Brown, Michael P, et al.
Publicado: (2019) -
Chimeric antigen receptors designed to overcome transforming growth factor‐β‐mediated repression in the adoptive T‐cell therapy of solid tumors
por: Hartley, Jordan, et al.
Publicado: (2019) -
CRISPR/Cas9 mediated deletion of the adenosine A2A receptor enhances CAR T cell efficacy
por: Giuffrida, Lauren, et al.
Publicado: (2021)